Sustained response to trametinib in an adult patient with neurofibromatosis type 1 and high-grade glioma.
Details
Serval ID
serval:BIB_689CAC58A4EB
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Sustained response to trametinib in an adult patient with neurofibromatosis type 1 and high-grade glioma.
Journal
Child's nervous system
ISSN
1433-0350 (Electronic)
ISSN-L
0256-7040
Publication state
Published
Issued date
04/06/2025
Peer-reviewed
Oui
Volume
41
Number
1
Pages
202
Language
english
Notes
Publication types: Case Reports ; Journal Article
Publication Status: epublish
Publication Status: epublish
Abstract
We report the case of a 25-year-old female patient with neurofibromatosis type 1 who was diagnosed with a thalamic high-grade glioma (HGG). She was initially treated with a combination of radiotherapy and concurrent temozolomide (TMZ). Following 7 months of TMZ treatment, an MRI showed tumor progression. Empiric treatment with trametinib was started, which demonstrated significant regression of the lesion. She is currently alive with stable disease 4 years post-initial diagnosis.
Keywords
Humans, Female, Pyridones/therapeutic use, Adult, Neurofibromatosis 1/complications, Neurofibromatosis 1/drug therapy, Neurofibromatosis 1/diagnostic imaging, Pyrimidinones/therapeutic use, Glioma/drug therapy, Glioma/complications, Glioma/diagnostic imaging, Brain Neoplasms/drug therapy, Brain Neoplasms/complications, Brain Neoplasms/diagnostic imaging, Magnetic Resonance Imaging, Antineoplastic Agents/therapeutic use, Temozolomide, HGAP, High-grade glioma (HGG), Neurofibromatosis type 1 (NF1), Targeted therapy, Trametinib
Pubmed
Create date
07/06/2025 12:19
Last modification date
08/06/2025 7:17